Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer.
第一作者:
Xinyi,Yang
第一单位:
Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
作者:
主题词
人类(Humans);女(雌)性(Female);中年人(Middle Aged);乳房切除术(Mastectomy);细胞因子诱导杀伤细胞(Cytokine-Induced Killer Cells);预后(Prognosis);免疫疗法(Immunotherapy);杀伤细胞, 天然(Killer Cells, Natural);佐剂, 药物(Adjuvants, Pharmaceutic);免疫因子类(Immunologic Factors);佐剂, 免疫(Adjuvants, Immunologic)
DOI
10.3389/fimmu.2022.974487
PMID
36439119
发布时间
2022-11-29
- 浏览0
Frontiers in immunology
974487页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文